Linked Life Data

9718589

Source:http://linkedlifedata.com/resource/pubmed/id/9718589

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1998-11-25
pubmed:abstractText
Recent preclinical evidence suggests that repeated exposure to 3, 4-methylenedioxy-methamphetamine (MDMA; "ecstasy") produces long-term reductions in serotonin (5-HT) levels. 5-HT has been implicated in the regulation of mood, anxiety, aggression, impulsivity, and cognition. Accordingly, in the first of two separate studies, these variables were investigated in three groups: (1) MDMA group--recreational ecstasy users (who also used other illicit substances); (2) polydrug controls--who had never taken ecstasy, but otherwise had drug histories and personal characteristics similar to the ecstasy users; and (3) nondrug controls--who had never used illicit drugs, but had similar personal characteristics. All participants completed mood (Likert) scales, personality questionnaires (which included the impulsiveness, venturesomeness and empathy questionnaire-IVE), spatial span and "Tower of London" (TOL) tests, and a behavioural measure of impulsivity, the matching familiar figures test (MFF20). There were no group differences in mood, anxiety, anger/hostility, and cognitive performance, but the MDMA group committed significantly more errors in the MFF20. Subsequently, a larger sample of participants were administered mood (the General Health Questionnaire or GHQ) and personality (IVE) questionnaires before the administration of a TOL test, followed by the MFF20, and a second TOL test. Although there were no group differences in TOL performance, ecstasy users were again found to commit more errors in the MFF20 than polydrug users. Furthermore, the GHQ and IVE scores of the ecstasy users in the second study indicated, respectively, that they were more psychologically disturbed and impulsive than nondrug controls. The combined data from the two studies indicated that ecstasy users exhibited elevated impulsivity on both self-report and behavioral measures and that those who had taken the most ecstasy had the most elevated trait impulsiveness scores. These findings are consistent with previous evidence that elevated levels of impulsivity in humans are associated with reduced levels of serotonergic function.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0893-133X
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
252-64
pubmed:dateRevised
2011-5-18
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity.
pubmed:affiliation
Department of Psychology, University of Wales, Swansea, S. Wales, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study